Table 3 |
|
|
A selection of cancer-unrelated SL partners of cancer-related genes and their associated drugs. |
|
|
Drug-target name |
Drug (Description) |
|
|
|
|
CDC25B |
Beta-Mercaptoethanol (Glutathione S-Transferase inhibitor); Cysteinesulfonic Acid(Peroxiredoxin inhibitor); Double Oxidized Cysteine (Peptide Deformylase Pdf1 inhibitor) |
|
CDC42 |
Aminophosphonic Acid-Guanylate Ester (G25K GTP-Binding Protein inhibitor) |
|
CDK2 |
4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine (Cell Division Protein Kinase 2 inhibitor) |
|
DDX6 |
D-tartaric acid (D-tartaric acid) |
|
EIF4E |
7-Methyl-Gpppa (Eukaryotic Translation Initiation Factor 4E inhibitor); 7n- Methyl-8-Hydroguanosine-5'-Diphosphate (Vp39 inhibitor) |
|
GDI1 |
Geran-8-Yl Geran(Rab GDP Disossociation Inhibitor Alpha inhibitor) |
|
GRB2 |
4- [(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo- 7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid (Growth Factor Receptor-Bound Protein 2 inhibitor) |
|
HSP90AB1 |
9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine (Heat Shock Protein Hsp 90-Beta inhibitor) |
|
HSPA5 |
antihemophilic factor (Coagulation factor VIII precursor) |
|
LSS |
Dihydrofolic Acid (Dihydrofolate Reductase inhibitor) |
|
PPP1CC |
9,10-Deepithio-9,10-Didehydroacanthifolicin (Serine/Threonine Protein Phos phatase Pp1-Gam inhibitor) |
|
PPP2CA |
Vitamin E (Dietary supplement) |
|
PPP3R2 |
Cyclosporine (Investigational Immunomodulatory Agents; Immunosuppressive Agents; Antifungal Agents; Dermatologic Agents; Enzyme Inhibitors; An tirheumatic Agents For treatment of transplant rejection, rheumatoid arthritis, severe psoriasis) |
|
PRDX2 |
3-Sulfinoalanine (3-Hydroxy-3-Methylglutaryl-Coa Synthase inhibitor) |
|
SEC14L2 |
Palmitic Acid (Enzyme Inhibitors) |
|
SNAP25 |
Botulinum Toxin Type A (Anti-Wrinkle Agents; Antidystonic Agents; Neuromuscular Blocking Agents) |
|
SOD1 |
S-Oxy Cysteine (Prolyl Oligopeptidase inhibitor) |
|
SQLE |
Naftifine (Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents) |
|
|
|
|
These drugs are not oriented to anti-cancer treatment. In this list we excluded general metabolites described as dietary supplements in DrugBank. A short description of drug activities are provided in parenthesis. |
|
|
Conde-Pueyo et al. BMC Systems Biology 2009 3:116 doi:10.1186/1752-0509-3-116 |
|